Tissues, Cells and Biomarkers in ARDS
Journal of Cellular & Molecular Anesthesia,
Vol. 1 No. 1 (2016),
21 December 2015
,
Page 43-44
https://doi.org/10.22037/jcma.v1i1.10576
Abstract
The utility of biomarkers for the action of endothelium and epithelium of the pulmonary microvasculars is unknown and their action of being barrier for edema and dysfunction of them cause ARDS and its mortality rate with no specific drugs efficiency is high (1).
Recently, there are many important information about biomarkers in ARDS (2). These biomarkers in ARDS can effect either cellular activation or cell injury. Currently, biomarkers are the most important research tool. The biomarkers have an important role in ARDS treatment in the function.
There is an executive phase with some damage like edema and necroses. Then, fibro-proliferative phase will be happen. To understand the mechanism of repair, we focus on the function of alveolar type I (3).
- ARDS
- cell
- tissue
- biomarker
How to Cite
References
.Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-33.
Kassiri N, Hashemian SM. ARDS Definition Evolution: Past and Future Quotes. J Anesth Clin Res. 2014;5(11).
Hashemian SM, Mortaz E, Tabarsi P, Jamaati H, Maghsoomi Z, Khosravi A, et al. Elevated CXCL-8 expression in bronchoalveolar lavage correlates with disease severity in patients with acute respiratory distress syndrome resulting from tuberculosis. J Inflamm (Lond). 2014;11:21.
Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet. 1993;341(8846):643-7.
Hirani N, Antonicelli F, Strieter RM, Wiesener MS, Ratcliffe PJ, Haslett C, et al. The regulation of interleukin-8 by hypoxia in human macrophages--a potential role in the pathogenesis of the acute respiratory distress syndrome (ARDS). Mol Med. 2001;7(10):685-97.
Ware LB, Koyama T, Zhao Z, Janz DR, Wickersham N, Bernard GR, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care. 2013;17(5):R253.
Ware LB, Bastarache JA, Wang L. Coagulation and fibrinolysis in human acute lung injury--new therapeutic targets? Keio J Med. 2005;54(3):142-9.
Medford AR, Millar AB. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm? Thorax. 2006;61(7):621-6.
Parikh SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence. 2013;4(6):517-24.
Calfee CS, Gallagher D, Abbott J, Thompson BT, Matthay MA. Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance. Crit Care Med. 2012;40(6):1731-7.
Fujishima S. Pathophysiology and biomarkers of acute respiratory distress syndrome. J Intensive Care. 2014;2(1):32.
Siemiatkowski A, Kloczko J, Galar M, Czaban S. von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury. Haemostasis. 2000;30(4):189-95.
- Abstract Viewed: 391 times
- PDF Downloaded: 289 times